secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bone Biologics Corp (BBLG)
CIK:        0001419554
Form:       8-K
Filed at:   2022-10-25T23:59:59+00:00
Accession:  0001493152-22-029492
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bone Biologics CEO letter details $5.1M financing, plans for 30-patient NB1 trial in Australia by 2023
--------------------------------------------------------------------------------

- Raised $5.1M gross in underwritten public offering of common stock and warrants for clinical trials and working capital.
- Modified license agreement with UCLA TDG in May 2022 to defer diligence fees until first product sale.
- Engaged MTF Biologics for DBM supply and a CDMO for recombinant protein manufacturing for NB1.
- Expects to commence 30-patient pilot study in Australia in 2023 evaluating NB1 in lumbar interbody fusion.
- NB1 addresses $3B global market for bone graft substitutes in spine fusion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419554/000149315222029492/0001493152-22-029492-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419554/000149315222029492/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-029492

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer